Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells
文献类型：期刊论文
| 作者 | He, Chang-xi1; Ai, Jing1 ; Xing, Wei-qiang2; Chen, Yi1; Zhang, Hao-tian1; Huang, Min1; Hu, You-hong2; Ding, Jian1; Geng, Mei-yu1
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2014-01 |
| 卷号 | 35期号:1页码:89-97 |
| 关键词 | human cancer anticancer drug Yhhu3813 c-Met receptor tyrosine kinase xenograft nude mouse model |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/aps.2013.125 |
| 文献子类 | Article |
| 英文摘要 | Aim: c-Met kinase deregulation is strongly associated with the formation, progression and dissemination of human cancers. In this study we identified Yhhu3813 as a small-molecule inhibitor of c-Met kinase and characterized its antitumor properties both in vitro and in vivo. Methods: The activities of different kinases were measured using ELISA assays and signaling proteins in the cells were detected with Western blotting. Cell proliferation was assessed using SRB or MTT assay in twenty human cell lines and cell cycle distribution was determined with flow cytometry. Transwell-based assay was used to evaluate cell migration and invasion. Cell invasive growth was detected by a morphogenesis assay. c-Met overactivated human NSCLC cell line EBC-1 xenografts were used to evaluate the in vivo anti-tumor efficacy. Results: Yhhu3813 potently inhibited c-Met kinase activity in vitro with an IC50 value of 2.4 +/- 0.3 nmol/L, > 400-fold higher than that for a panel of 15 different tyrosine kinases, suggesting a high selectivity of Yhhu3813. The compound (20, 100 and 500 nmol/L) dose-dependently inhibited the phosphorylation of c-Met and its key downstream Akt and Erk signal cascades in multiple c-Met aberrant human cancer cell lines, regardless of the mechanistic complexity in c-Met activation across different cellular contexts. In 20 human cancer cell lines harboring different backgrounds of c-Met expression/activation, Yhhu3813 potently inhibited c-Met-driven cell proliferation via arresting cells at G(1)/S phase. Furthermore, Yhhu3813 substantially impaired c-Met-mediated cell migration, invasion, scattering, and invasive growth. Oral administration of EBC-1 xenograft mice with Yhhu3813 (50 or 100 mg.kg(-1).d(-1), qd, for 2 weeks) dose-dependently suppressed the tumor growth, which was correlated with a reduction in the intratumoral proliferation index and c-Met signaling. Conclusion: Yhhu3813 is a potent selective inhibitor of c-Met that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells in vitro and in vivo. |
| WOS关键词 | HEPATOCYTE GROWTH-FACTOR ; EPITHELIAL-MESENCHYMAL TRANSITION ; RECEPTOR TYROSINE KINASES ; FACTOR/SCATTER FACTOR ; TUMOR PROGRESSION ; PROSTATE-CANCER ; INVASIVE GROWTH ; LUNG-CANCER ; HGF ; PROTOONCOGENE |
| 资助项目 | National Program on Key Basic Research Project of China[2012CB910704] ; Natural Science Foundation of China for Innovation Research Group[81021062] ; National Natural Science Foundation of China[81102461] ; National S&T Major Projects[2012ZX09301001-007] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| CSCD记录号 | CSCD:5040815 |
| WOS记录号 | WOS:000330581000011 |
| 出版者 | ACTA PHARMACOLOGICA SINICA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/277317]  |
| 专题 | 药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室 |
| 通讯作者 | Geng, Mei-yu |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Med Chem, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | He, Chang-xi,Ai, Jing,Xing, Wei-qiang,et al. Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells[J]. ACTA PHARMACOLOGICA SINICA,2014,35(1):89-97. |
| APA | He, Chang-xi.,Ai, Jing.,Xing, Wei-qiang.,Chen, Yi.,Zhang, Hao-tian.,...&Geng, Mei-yu.(2014).Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.ACTA PHARMACOLOGICA SINICA,35(1),89-97. |
| MLA | He, Chang-xi,et al."Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells".ACTA PHARMACOLOGICA SINICA 35.1(2014):89-97. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。